Najat Khan, Chief Commercial Officer at The Janssen Pharmaceutical Companies and board member at Recursion, shared on LinkedIn:

“It’s bittersweet to announce my resignation from my role as the Chief Data Science Officer and Global Head, Strategy and Portfolio Organization of Johnson and Johnson Innovative Medicine’s R and D organization after six incredible years to take on a new opportunity to serve as Chief R and D Officer and Chief Commercial Officer and join the esteemed Board at Recursion.

Times of changes are always times of reflection, and I’m incredibly grateful for the opportunities I’ve had at J and J and, most importantly, the incredible people and teams who have been part of my journey.

THANK YOU to my Strategy and Portfolio Organization team for their crucial role in developing an industry-leading strategic vision and pipeline and enhancing our organisational productivity over six years. Your collaborative ONE TEAM spirit, your creativity, and your relentless ‘can-do’ attitude have guided us through challenges and driven huge successes across our portfolio.

THANK YOU to my Data Science and Digital Health team, which we built from the ground up into an extraordinary, world-class power house of bilingual talent – with expertise in both biopharma and data science – that is pioneering groundbreaking innovation and setting new benchmarks within the pharmaceutical industry. Your relentless dedication, resilience and willingness to challenge the statusquo have helped us convert vision to reality, leveraging the biggest opportunities to drive at scale impact for our pipeline and for patients.

THANK YOU to the J and J Data Science Council, my Co-Chair Peter Schulam and the 20+ members across J and J. Our deep collaboration has demonstrated real impact and set standards on AI and ethics, talent recruitment and development, and more.

A heartfelt THANK YOU to Joaquin Duato, for your unwavering support and inspiring leadership, and to John C. Reed and William N. Hait for your steadfast mentorship and guidance. And THANK YOU to those on the J and J Executive Committee, Group Operating Committee, and the R and D Senior Leadership Team for being outstanding mentors and partners.

As I embark on a new adventure with Recursion – a company at the forefront of the Bio Technology sector – I am excited to collaborate with Chris Gibson and the brilliant team to drive the company’s mission of leveraging the power of sophisticated AI/ML algorithms, computational power, and extensive experience in science and medicine to pioneer new ways of discovering and developing new medicines. I am thrilled to lead and build on Recursion’s innovative R and D efforts and create innovative Commercial strategies to ensure our scientific breakthroughs reach patients in need efficiently and effectively. Read more.

To my team, colleagues, and mentors: THANK YOU for the cherished memories and invaluable lessons. This isn’t goodbye, but a ‘see you later,’ as our paths are sure to cross again, bringing new opportunities for collaboration and growth.

With sincere appreciation and best wishes – Najat.”

Source: Najat Khan/LinkedIn